Quidel Receives FDA Clearance for Lyra Molecular PCR Assay for Detection of Infections From Pyogenic Streptococcus Group A and C or G

Quidel has received clearance, via the De Novo Request process, from the FDA to market its Lyra Direct Strep Assay, a multiplex real-time PCR assay. This new molecular test detects and differentiates between pyogenic Group A and pyogenic C or G Streptococcal throat infections.
DeviceSpace